BACKGROUND: The HER2 (human epidermal growth factor receptor-2) Ile655Val (rs1136201) genetic polymorphism can alter the receptor structure and its auto-activation, which can modify the signal transduction and, consequently, the cell cycle regulation. For this reason, this polymorphism has been extensively investigated as a candidate marker for breast cancer (BC). In this context, the aim of this study was to evaluate the possible influence of HER2 Ile655Val in BC susceptibility and prognostic factors in a Brazilian population. METHODS: Polymorphism genotype was assessed through RFLP-PCR in 107 BC patients with clinicopathological data available and in 150 women with no evidence of neoplasia and with no familial history of BC as control group. Association between this polymorphism and BC susceptibility and clinical parameters was evaluated through odds ratio (OR) and chi-squared or Fisher's exact test, respectively. RESULTS: A significant negative association between valine allele and BC susceptibility in dominant model was found (OR 0.5; 95% CI 0.27-0.93, P = .036). No significant association was found in relation to BC clinicopathological features (tumor size, lymph nodes commitment, histological grade, HER2 overexpression, hormonal receptors, p53, and Ki-67). CONCLUSION: Although this polymorphism did not demonstrate potential as a prognostic marker, it may be a suitable susceptibility marker for BC.
BACKGROUND: The HER2 (humanepidermal growth factor receptor-2) Ile655Val (rs1136201) genetic polymorphism can alter the receptor structure and its auto-activation, which can modify the signal transduction and, consequently, the cell cycle regulation. For this reason, this polymorphism has been extensively investigated as a candidate marker for breast cancer (BC). In this context, the aim of this study was to evaluate the possible influence of HER2Ile655Val in BC susceptibility and prognostic factors in a Brazilian population. METHODS: Polymorphism genotype was assessed through RFLP-PCR in 107 BC patients with clinicopathological data available and in 150 women with no evidence of neoplasia and with no familial history of BC as control group. Association between this polymorphism and BC susceptibility and clinical parameters was evaluated through odds ratio (OR) and chi-squared or Fisher's exact test, respectively. RESULTS: A significant negative association between valine allele and BC susceptibility in dominant model was found (OR 0.5; 95% CI 0.27-0.93, P = .036). No significant association was found in relation to BC clinicopathological features (tumor size, lymph nodes commitment, histological grade, HER2 overexpression, hormonal receptors, p53, and Ki-67). CONCLUSION: Although this polymorphism did not demonstrate potential as a prognostic marker, it may be a suitable susceptibility marker for BC.
Authors: M Elizabeth H Hammond; Daniel F Hayes; Antonio C Wolff; Pamela B Mangu; Sarah Temin Journal: J Oncol Pract Date: 2010-06-23 Impact factor: 3.840
Authors: Salma Parvin; Md Siddiqul Islam; Mir Md Abdullah Al-Mamun; Mohammad Safiqul Islam; Maizbha Uddin Ahmed; Eva Rahman Kabir; Abul Hasnat Journal: Breast Cancer Date: 2016-04-11 Impact factor: 4.239
Authors: S Beauclair; P Formento; J L Fischel; W Lescaut; R Largillier; E Chamorey; P Hofman; J M Ferrero; G Pagès; G Milano Journal: Ann Oncol Date: 2007-08 Impact factor: 32.976
Authors: Tung Nguyen Thanh; Bao Song Nguyen Tran; Ai Phuong Hoang Thi; Thang Tran Binh; Thong Ba Nguyen; Tam Le Minh; Quoc Huy Nguyen Vu; Thuan Dang Cong Journal: Asian Pac J Cancer Prev Date: 2021-01-01
Authors: Ibrahim O Alanazi; Jilani Purusottapatnam Shaik; Narasimha Reddy Parine; Nahla A Azzam; Othman Alharbi; Yousef M Hawsawi; Atif Abdulwahab A Oyouni; Osama M Al-Amer; Faisal Alzahrani; Majid A Almadi; Abdulrahman M Aljebreen; Mohammad Saud Alanazi; Zahid Khan Journal: J Oncol Date: 2021-10-21 Impact factor: 4.375